Looking at this filing, I need to identify the key financial details from Pfizer's 10-Q for the quarterly period ended September 27, 2026. The filing content provided is primarily the cover page, table of contents, and defined terms sections. I'll work with what is substantively disclosed. The substantive content includes: the filing type and period, share count (5,699,853,733 shares outstanding at October 28, 2026), the securities registered (multiple note series), the company's status as a large accelerated filer, and details about Paxlovid's EUA status including the June 30, 2026 HHS announcement about termination of COVID-19 EUA declarations effective June 29, 2027. This is well above 150 words of substantive content, so I proceed.

Pfizer Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 3, 2026, covering the fiscal quarter ended September 27, 2026.

Key Highlights

  • Share count: 5,699,853,733 shares of voting common stock were outstanding as of October 28, 2026, according to the filing.
  • Large accelerated filer: Pfizer indicated it qualifies as a large accelerated filer under Rule 12b-2 of the Exchange Act.
  • Paxlovid EUA update: The filing disclosed that on June 30, 2026, the U.S. Department of Health and Human Services announced the termination of COVID-19 EUA declarations for drugs and biological products, effective June 29, 2027.
  • Multiple securities listed: In addition to common stock, five series of notes are registered on the New York Stock Exchange, with maturities ranging from 2027 to 2045.
  • Fiscal period scope: For U.S. subsidiaries, the quarter covers three and nine months ended September 27, 2026; for non-U.S. subsidiaries, the quarter-end is August 23, 2026.

Pfizer's Third Quarter 2026 Quarterly Filing: Key Disclosures

Pfizer Inc. (NYSE:PFE), incorporated in Delaware and headquartered at 66 Hudson Boulevard East, New York, New York 10001-2192, submitted its Form 10-Q for the quarterly period ended September 27, 2026. The filing confirms that as of October 28, 2026, the company had 5,699,853,733 shares of voting common stock outstanding.

The filing notes that Pfizer's fiscal quarter-end differs by geography: for subsidiaries operating outside the U.S., the period is as of and for the three and nine months ended August 23, 2026 and August 24, 2025, while for U.S. subsidiaries it is as of and for the three and nine months ended September 27, 2026 and September 28, 2025. The company registered six classes of securities on the New York Stock Exchange, including common stock (par value $0.05) and five series of notes: 1.000% Notes due 2027 (PFE/27), 2.875% Notes due 2029 (PFE/29), 3.250% Notes due 2032 (PFE/32), 3.875% Notes due 2037 (PFE/37A), and 4.250% Notes due 2045 (PFE/45).

Regarding Paxlovid, the filing disclosed that the product has not been approved but has been authorized for emergency use by the FDA for treatment of mild-to-moderate COVID-19 in certain pediatric patients. The filing further noted that "on June 30, 2026, the U.S. Department of Health and Human Services announced the termination of the COVID-19 EUA declarations for drugs and biological products, effective June 29, 2027." The company also confirmed it has filed all required reports under Section 13 or 15(d) of the Exchange Act during the preceding 12 months and has submitted all required Interactive Data Files electronically.

What Was Disclosed

Pfizer filed its Form 10-Q for the quarter ended September 27, 2026, reporting 5,699,853,733 shares outstanding as of October 28, 2026, disclosing registered debt securities on the NYSE, and updating the status of Paxlovid's emergency use authorization.